NASDAQ:PAVM PAVmed (PAVM) Stock Price, News & Analysis $0.66 +0.01 (+1.72%) (As of 12:59 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About PAVmed Stock (NASDAQ:PAVM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PAVmed alerts:Sign Up Key Stats Today's Range$0.57▼$0.6650-Day Range$0.58▼$1.1852-Week Range$0.57▼$4.44Volume388,962 shsAverage Volume77,983 shsMarket Capitalization$7.26 millionP/E RatioN/ADividend YieldN/APrice Target$19.00Consensus RatingStrong Buy Company OverviewPAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.Read More… PAVmed Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks76th Percentile Overall ScorePAVM MarketRank™: PAVmed scored higher than 76% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingPAVmed has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePAVmed has only been the subject of 1 research reports in the past 90 days.Read more about PAVmed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for PAVmed are expected to grow in the coming year, from ($5.17) to ($4.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PAVmed is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PAVmed is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.12% of the float of PAVmed has been sold short.Short Interest Ratio / Days to CoverPAVmed has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in PAVmed has recently increased by 6.15%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPAVmed does not currently pay a dividend.Dividend GrowthPAVmed does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-0.78 Percentage of Shares Shorted3.12% of the float of PAVmed has been sold short.Short Interest Ratio / Days to CoverPAVmed has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in PAVmed has recently increased by 6.15%, indicating that investor sentiment is decreasing significantly. News and Social Media1.0 / 5News Sentiment-0.18 News SentimentPAVmed has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for PAVmed this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added PAVmed to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PAVmed insiders have not sold or bought any company stock.Percentage Held by Insiders11.30% of the stock of PAVmed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.93% of the stock of PAVmed is held by institutions.Read more about PAVmed's insider trading history. Receive PAVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PAVmed and its competitors with MarketBeat's FREE daily newsletter. Email Address PAVM Stock News HeadlinesPAVmed stock plunges to 52-week low, touches $0.6December 20, 2024 | investing.comLucid Diagnostics partners for esophageal precancer detection for firefightersDecember 19, 2024 | markets.businessinsider.comTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… December 24, 2024 | Crypto 101 Media (Ad)Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for FirefightersDecember 19, 2024 | prnewswire.comLucid announces publication on EsoGuard in peer-reviewed journal MedicinaDecember 12, 2024 | markets.businessinsider.comProspective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed PublicationDecember 11, 2024 | prnewswire.comLucid Diagnostics completes convertible debt refinancingDecember 4, 2024 | markets.businessinsider.comLucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term MilestonesDecember 3, 2024 | prnewswire.comSee More Headlines PAVM Stock Analysis - Frequently Asked Questions How have PAVM shares performed this year? PAVmed's stock was trading at $4.12 at the start of the year. Since then, PAVM shares have decreased by 84.5% and is now trading at $0.64. View the best growth stocks for 2024 here. How were PAVmed's earnings last quarter? PAVmed Inc. (NASDAQ:PAVM) released its quarterly earnings results on Thursday, August, 12th. The company reported ($2.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.50) by $0.60. When did PAVmed's stock split? Shares of PAVmed reverse split before market open on Thursday, December 7th 2023. The 1-15 reverse split was announced on Thursday, December 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of PAVmed? Shares of PAVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of PAVmed own? Based on aggregate information from My MarketBeat watchlists, some other companies that PAVmed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), Pfizer (PFE). Company Calendar Last Earnings8/12/2021Today12/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:PAVM CUSIPN/A CIK1624326 Webwww.pavmed.com Phone(212) 949-4319FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$19.00 Low Stock Price Target$19.00 Potential Upside/Downside+2,868.8%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($4.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-64,180,000.00 Net Margins602.97% Pretax Margin244.87% Return on EquityN/A Return on Assets-92.36% Debt Debt-to-Equity RatioN/A Current Ratio0.06 Quick Ratio0.06 Sales & Book Value Annual Sales$4.03 million Price / Sales1.76 Cash FlowN/A Price / Cash FlowN/A Book Value($3.35) per share Price / Book-0.19Miscellaneous Outstanding Shares11,069,000Free Float9,442,000Market Cap$7.08 million OptionableOptionable Beta0.67 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:PAVM) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredTiny Mineral, Massive Market OpportunityImagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's f...i2i Marketing Group, LLC | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredWall St. Icon: “If you wait on this, it will already be too late”If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PAVmed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PAVmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.